Presentation is loading. Please wait.

Presentation is loading. Please wait.

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis  Benjamin Chimukangara,

Published byRémi Aubin Modified over 5 years ago

Similar presentations

Presentation on theme: "Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis  Benjamin Chimukangara,"— Presentation transcript:

1 Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis  Benjamin Chimukangara, Richard J. Lessells, Soo-Yon Rhee, Jennifer Giandhari, Ayesha B.M. Kharsany, Kogieleum Naidoo, Lara Lewis, Cherie Cawood, David Khanyile, Kassahun A. Ayalew, Karidia Diallo, Reshmi Samuel, Gillian Hunt, Alain Vandormael, Babill Stray-Pedersen, Michelle Gordon, Tariro Makadzange, Photini Kiepiela, Gita Ramjee, Johanna Ledwaba, Monalisa Kalimashe, Lynn Morris, Urvi M. Parikh, John W. Mellors, Robert W. Shafer, David Katzenstein, Pravi Moodley, Ravindra K. Gupta, Deenan Pillay, Salim S. Abdool Karim, Tulio de Oliveira  EClinicalMedicine  DOI: /j.eclinm Copyright © Terms and Conditions

2 Fig. 1 Flow diagram of articles and datasets identified and selected for the pooled sequence analysis of PDR in antiretroviral therapy-naive adults in South Africa. EClinicalMedicine DOI: ( /j.eclinm ) Copyright © Terms and Conditions

3 Fig. 2 Prevalence of pretreatment HIV drug resistance by year of sampling. A) Overall, B) non-nucleoside reverse-transcriptase inhibitor, C) nucleoside reverse-transcriptase inhibitor, D) protease inhibitor. Each bubble represents a dataset and the size of the bubble is proportional to the number of sequences in the dataset. The sampling year is shown on the horizontal axis and the percentage PDR on the vertical axis. PDR, pretreatment HIV drug resistance. EClinicalMedicine DOI: ( /j.eclinm ) Copyright © Terms and Conditions

4 Fig. 3 Prevalence of specific mutations in HIV-1 sequences with any drug resistance mutation. Mutations shown on the horizontal axis include all mutations observed in >1% of the sequences with any drug resistance mutation. DRM, drug resistance mutation. EClinicalMedicine DOI: ( /j.eclinm ) Copyright © Terms and Conditions

Download ppt "Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis  Benjamin Chimukangara,"

Similar presentations

Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.

Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.
Global HIV Resistance: The Implications of Transmission

Global HIV Resistance: The Implications of Transmission
HIV Genotyping: Sharing Experiences and Protocols Justen Manasa PhD Candidate Africa Centre for Health and Population Studies Virology laboratory based.

HIV Genotyping: Sharing Experiences and Protocols Justen Manasa PhD Candidate Africa Centre for Health and Population Studies Virology laboratory based.
Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.

Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.
© 2011. IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4):156-164. Updates, user notes, and references available at www.iasusa.org. Mutations in the.

© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.
Increased phenotypic susceptibility (hypersusceptibility, HS) to NNRTIs is observed in ~30% of viral isolates with NRTI- resistance mutations 1 and has.

Increased phenotypic susceptibility (hypersusceptibility, HS) to NNRTIs is observed in ~30% of viral isolates with NRTI- resistance mutations 1 and has.
SATuRN HIV-1 Genotyping System Justen Manasa Africa Centre for Health and Population Studies Virology laboratory based at the Nelson R. Mandela School.

SATuRN HIV-1 Genotyping System Justen Manasa Africa Centre for Health and Population Studies Virology laboratory based at the Nelson R. Mandela School.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 29.6 The Steps in HIV Replication Slide number 1 (1) Viral.

Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display The Steps in HIV Replication Slide number 1 (1) Viral.
How Does Antiretroviral Therapy Affect HIV Mutation and Vice Versa? Arlin Toro Devin Iimoto Devin Iimoto.

How Does Antiretroviral Therapy Affect HIV Mutation and Vice Versa? Arlin Toro Devin Iimoto Devin Iimoto.
Epidémiologie Problème mondial / problématique en fonction de l’âge et le sexe Mise en place de la prophylaxie.

Epidémiologie Problème mondial / problématique en fonction de l’âge et le sexe Mise en place de la prophylaxie.
Will Drug Resistance Jeopardize the National HIV Drug Resistance Programme? Prof. Tulio de Oliveira Africa Centre for Health and Population Studies, University.

Will Drug Resistance Jeopardize the National HIV Drug Resistance Programme? Prof. Tulio de Oliveira Africa Centre for Health and Population Studies, University.
Washington D.C., USA, 22-27 July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.

Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
Date of download: 5/28/2016 From: When to Start Antiretroviral Therapy in Resource-Limited Settings Ann Intern Med. 2009;151(3):157-166. doi:10.7326/0003-4819-151-3-200908040-00138.

Date of download: 5/28/2016 From: When to Start Antiretroviral Therapy in Resource-Limited Settings Ann Intern Med. 2009;151(3): doi: /
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.
© 2013. IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at www.iasusa.org. Mutations in the Reverse.

© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.
Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.

Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.
High prevalence of antiretroviral drug resistance among HIV-infected pregnant women in Buenos Aires, Argentina Zapiola 1, D.M. Cecchini 2, S. Fernandez.

High prevalence of antiretroviral drug resistance among HIV-infected pregnant women in Buenos Aires, Argentina Zapiola 1, D.M. Cecchini 2, S. Fernandez.
HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action IAS 2017 Paris 24th July 2017 Modelling the cost and cost-effectiveness.

HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action IAS 2017 Paris 24th July 2017 Modelling the cost and cost-effectiveness.
Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of.

Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of.
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Similar presentations

Ads by Google